Acrobiosystems Co.,Ltd. (SHE:301080)
China · Delayed Price · Currency is CNY 44.47
-1.79 (-3.87%)
At close: May 12, 2026
Acrobiosystems Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 872.65 | 823.56 | 632.94 | 532.8 | 466.58 | 376.71 |
Other Revenue | 14.56 | 14.56 | 12.09 | 10.85 | 7.85 | 8.28 |
| 887.21 | 838.12 | 645.02 | 543.65 | 474.43 | 384.99 | |
Revenue Growth (YoY) | 29.42% | 29.94% | 18.65% | 14.59% | 23.23% | 56.30% |
Cost of Revenue | 143.29 | 138.55 | 98.24 | 85.14 | 59.01 | 34.27 |
Gross Profit | 743.92 | 699.57 | 546.78 | 458.52 | 415.42 | 350.72 |
Selling, General & Admin | 409.98 | 389.6 | 321.28 | 254.64 | 185.23 | 115.81 |
Research & Development | 185.1 | 182.33 | 161.87 | 122.22 | 112.47 | 59.55 |
Other Operating Expenses | 13.26 | 7.78 | 2.68 | 2.3 | 0.8 | 0.73 |
Operating Expenses | 610.48 | 581.87 | 487.3 | 379.85 | 299.12 | 177.09 |
Operating Income | 133.44 | 117.7 | 59.48 | 78.67 | 116.3 | 173.63 |
Interest Expense | -0.99 | -2.69 | -3.54 | -2.7 | -2.95 | -1.15 |
Interest & Investment Income | 52.25 | 56.09 | 61.91 | 60.92 | 63.25 | 10.72 |
Currency Exchange Gain (Loss) | -9.88 | -9.88 | 3.56 | 10.87 | 15.5 | 1.42 |
Other Non Operating Income (Expenses) | -5.98 | -4.78 | -2.79 | -2.78 | -1.72 | -1.06 |
EBT Excluding Unusual Items | 168.85 | 156.45 | 118.61 | 144.99 | 190.39 | 183.56 |
Gain (Loss) on Sale of Investments | 4.09 | 4.55 | -1.48 | 0.66 | 0.62 | 0.06 |
Gain (Loss) on Sale of Assets | 0.07 | 0.07 | -0.35 | - | 0.21 | 0.28 |
Asset Writedown | -6.52 | -0.15 | -0 | -0.11 | -0.76 | -0.05 |
Other Unusual Items | 8.81 | 8.41 | 8.13 | 15.12 | 24.52 | 11.59 |
Pretax Income | 175.3 | 169.32 | 124.91 | 160.67 | 214.99 | 195.44 |
Income Tax Expense | 4.52 | 4.48 | 4.87 | 13.12 | 15.77 | 22 |
Earnings From Continuing Operations | 170.78 | 164.84 | 120.04 | 147.55 | 199.21 | 173.44 |
Minority Interest in Earnings | 0.46 | 0.72 | 3.79 | 6.04 | 4.52 | 0.78 |
Net Income | 171.25 | 165.57 | 123.83 | 153.59 | 203.73 | 174.21 |
Net Income to Common | 171.25 | 165.57 | 123.83 | 153.59 | 203.73 | 174.21 |
Net Income Growth | 28.04% | 33.70% | -19.38% | -24.61% | 16.95% | 50.34% |
Shares Outstanding (Basic) | 165 | 167 | 168 | 168 | 168 | 133 |
Shares Outstanding (Diluted) | 165 | 167 | 168 | 168 | 168 | 133 |
Shares Change (YoY) | -3.26% | -0.22% | -0.08% | -0.04% | 26.35% | 5.55% |
EPS (Basic) | 1.04 | 0.99 | 0.74 | 0.91 | 1.21 | 1.31 |
EPS (Diluted) | 1.04 | 0.99 | 0.74 | 0.91 | 1.21 | 1.31 |
EPS Growth | 32.36% | 33.99% | -19.31% | -24.58% | -7.44% | 42.43% |
Free Cash Flow | 140.82 | 150.66 | -82.56 | -17.49 | -82.1 | 76.31 |
Free Cash Flow Per Share | 0.85 | 0.90 | -0.49 | -0.10 | -0.49 | 0.57 |
Dividend Per Share | 0.600 | 0.600 | 0.500 | 0.643 | 0.714 | 0.714 |
Dividend Growth | 20.00% | 20.00% | -22.23% | -10.00% | - | - |
Gross Margin | 83.85% | 83.47% | 84.77% | 84.34% | 87.56% | 91.10% |
Operating Margin | 15.04% | 14.04% | 9.22% | 14.47% | 24.51% | 45.10% |
Profit Margin | 19.30% | 19.75% | 19.20% | 28.25% | 42.94% | 45.25% |
Free Cash Flow Margin | 15.87% | 17.98% | -12.80% | -3.22% | -17.30% | 19.82% |
EBITDA | 180.73 | 161.75 | 90.59 | 100.27 | 131.94 | 182.24 |
EBITDA Margin | 20.37% | 19.30% | 14.04% | 18.44% | 27.81% | 47.34% |
D&A For EBITDA | 47.29 | 44.05 | 31.11 | 21.6 | 15.64 | 8.61 |
EBIT | 133.44 | 117.7 | 59.48 | 78.67 | 116.3 | 173.63 |
EBIT Margin | 15.04% | 14.04% | 9.22% | 14.47% | 24.51% | 45.10% |
Effective Tax Rate | 2.58% | 2.65% | 3.90% | 8.16% | 7.34% | 11.26% |
Revenue as Reported | 887.21 | 838.12 | 645.02 | 543.65 | 474.43 | 384.99 |
Advertising Expenses | - | 70.06 | 53.69 | 52 | 35.84 | 32.85 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.